Pricing Log in Create free account
Saturday 17 October 2026 Export BTCY’s income statement to Excel — free account

Biotricity Inc.

BTCY Healthcare Medical Devices

Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025. In the quarter to June 2026, revenue grew 10.4%, EPS fell 66.7%, free cash flow grew 235.8% and total debt rose 3.48%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

0.05 0.00 0.00%
Market cap
$10.9M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
−33.34
Beneish M
−3.24
Dividend safety
n/a
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 87.75%

Capital & Financial Ratios $m

Market Cap 10.87
Revenue 16.40
Net Income (2.69)
Free Cash Flow 0.16
Net Debt 26.21
Current Ratio 0.15 (below 1: weak)
Debt/Equity (0.75) (negative: negative equity)
P/E ratio 0.00
Fwd P/E 0.00
P/S ratio 0.07
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 31.42% (at or above 15%: strong)
Next Y EPS Growth 72.26% (at or above 15%: strong)
Next Y revenue growth 14.57% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.7×, against a ten-year median of 5.9×; over the ten years it ranged from 1.7× in 2026 to 72.5× in 2019.
P/S against its own 10 years 0.52%
10-year low 10-year high
EV/Sales against its own 10 years 0.52%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 1 0 0 0
Receivables 1 2 3 2
Inventory 2 2 1 1
Other 0 1 1 1
4 5 6 6
2024 2025 2026 Q'26
Payables 10 8 9 9
ST’ Debt 12 12 26 26
Other 1 0 2 2
23 21 37 37

Compound Annual Growth %

10y 5y 3y
Sales — 36.43% 18.40%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Jun Sep Dec Mar Year
’26 4 — — — —
’26 4 4 4 4 16
’25 3 3 4 4 14
’24 3 3 3 3 12
’23 2 2 2 3 10
’22 2 2 2 2 8
’21 0 1 1 1 3
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 1 — — — —
’26 0 0 (1) 0 (1)
’25 (1) 0 0 0 (2)
’24 (2) (2) (1) (1) (7)
’23 (4) (4) (3) (2) (14)
’22 (3) (3) (4) (5) (15)
’21 (2) (2) (3) (4) (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 1 — — — —
’26 0 0 (1) 0 (1)
’25 (1) 0 0 0 (2)
’24 (2) (2) (1) (1) (7)
’23 (4) (4) (3) (2) (14)
’22 (3) (3) (5) (5) (15)
’21 (2) (2) (3) (4) (11)
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 (0.05) — — — —
’26 (0.03) (0.03) (0.04) (0.02) (0.11)
’25 (0.49) (0.07) (0.05) (0.06) (0.55)
’24 (0.39) (0.44) (0.34) (0.47) (1.66)
’23 (0.09) (0.54) (0.54) (0.54) (2.28)
’22 (0.90) (1.56) (0.90) (0.72) (4.02)
’21 (0.54) (0.48) (0.66) (0.90) (2.64)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 10.86 2.53 1.56 3.18 4.38 2.66 0.70 0.19 0.23 0.04

Analyst estimates 2027–2029

Powerpack
High 117.00 48.90 13.50 13.26 31.80 24.60 5.82 1.67 0.83 0.33
People
People Employees — — — — — — — — 46 46
Revenue/emp, $m — — 0.00 0.00 0.00 0.00 0.00 0.00 0.30 0.35
Income, $m
Income, $m Revenue — — 0 1 3 8 10 12 14 16
Gross margin, % — — 15.04 34.27 37.60 59.74 56.46 69.27 76.61 80.94
EBT (8) (9) (9) (11) (15) (29) (19) (14) (8) (2)
EBT margin, % 0.00 0.00 (2,157.73) (780.62) (457.67) (380.78) (193.57) (116.84) (61.07) (15.03)
Net income (8) (9) (9) (11) (15) (29) (19) (14) (8) (2)
Depreciation 1 1 — 0 2 9 1 2 2 1
Per share, $
Per share, $ Revenue 0.00 0.00 0.07 0.24 0.54 1.01 1.11 1.34 0.64 0.59
Earnings (1.74) (1.80) (1.52) (1.84) (2.64) (4.02) (2.28) (1.66) (0.55) (0.11)
Cash flow (0.87) (0.97) (0.94) (1.31) (1.77) (2.00) (1.56) (0.74) (0.11) (0.03)
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (0.87) (0.97) (0.94) (1.31) (1.77) (2.01) (1.56) (0.74) (0.11) (0.03)
Book value (1.02) 0.03 (0.32) (0.50) (1.09) (0.28) (2.29) (3.50) (1.49) (1.27)
Shares, m 4 5 6 6 6 8 9 9 22 27
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — 76.29 24.69 26.56 13.49 2.51 1.07 0.53 0.41
P/B — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales — — 78.39 25.50 27.28 13.74 4.30 2.87 2.33 2.07
EV/FCF — — (3.09) (4.60) (8.33) (6.92) (3.05) (5.14) (13.33) (44.16)
Cash, $m
Cash, $m Operating cash flow (4) (5) (5) (8) (11) (15) (14) (7) (2) (1)
Capex — — — — — 0 — — — —
Free cash flow (4) (5) (5) (8) (11) (15) (14) (7) (2) (1)
Balance, $m
Balance, $m Working capital (4) 0 (2) (2) (6) 10 (6) (18) (16) (31)
Total debt 2 — 1 2 5 14 18 22 25 27
Net debt 1 (1) 1 1 2 2 17 22 25 27
Shareholders’ equity (4) 0 (2) (3) (7) (2) (20) (31) (32) (35)
Returns, %
Returns, % ROA (2,886.99) (1,229.41) (1,210.07) (907.77) (510.78) (286.22) (168.48) (239.76) (206.19) (51.76)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE 184.76 409.52 1,071.00 474.03 334.63 673.20 177.66 58.19 37.62 9.38
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 28 Sep 2026

Charts ten years each

Biotricity Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IRIX IRIDEX Corporation $14.5M — (loss-making) — (loss-making) −7.41% (below 0%: shrinking) n/m +130.24% (above 0%: growing) 34.19% (8.19%) Compare
RBOT Vicarious Surgical Inc. $14.3M — (loss-making) — — n/m +47.33% (above 0%: growing) 0.00% 0.00% Compare
SINT SINTX TECHNOLOGIES, INC. $13.4M — (loss-making) — (loss-making) +199.34% (above 0%: growing) n/m −38.60% (below 0%: shrinking) 61.50% (638.94%) Compare
PETV PetVivo Holdings, Inc. $12.9M — (loss-making) — (loss-making) +13.48% (above 0%: growing) n/m +40.13% (above 0%: growing) 66.14% (476.54%) Compare
BTCY Biotricity Inc. $10.9M — (loss-making) — (loss-making) +10.40% (above 0%: growing) n/m +235.83% (above 0%: growing) 82.55% 3.70%
CTSO Cytosorbents Corporation $9.7M — (loss-making) — (loss-making) +0.17% (above 0%: growing) n/m +64.90% (above 0%: growing) 73.18% (27.39%) Compare
NMTC NeuroOne Medical Technologies Corporation $9.5M — (loss-making) — (loss-making) +16.33% (above 0%: growing) n/m +26.91% (above 0%: growing) 59.94% (122.87%) Compare
BMRA Biomerica, Inc. $8.6M — (loss-making) 11.4× +16.96% (above 0%: growing) n/m −35.05% (below 0%: shrinking) (7.88%) (174.77%) Compare
AEMD Aethlon Medical, Inc. $8.5M — (loss-making) — (loss-making) +335.00% (above 0%: growing) n/m −11.13% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $11.3M — — +16.33% — +33.52% 47.07% (75.13%)

All 149 Medical Devices stocks →

Biotricity Inc. (BTCY) key facts

  • Strength: Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025.
  • Biotricity Inc. (BTCY) is a Medical Devices company in the Healthcare sector.
  • As of October 16, 2026, BTCY traded at $0.05, a market capitalization of $10.9 million.
  • Return on equity was 9.38% and debt-to-equity -0.75.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −33.34 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.

Biotricity Inc. (BTCY) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BTCY · Data as of Sep 28, 2026 · For information only; not investment advice. · © 2026 stockrow.com